drugset
drugset / Trial / NCT06998056

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056 ↗

Phase 2 Completed 101 enrolled Arcutis Biotherapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Timeline

Start
2025-06-09
Primary completion
2025-12-04
Completion
2025-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.05 % Topical

Indications

atopic eczema